Verrica Pharmaceuticals' lead product YCANTH receives NCE status and Orange Book listing, granting 5 years of regulatory exclusivity.

Verrica Pharmaceuticals announces its lead product, YCANTH, receives New Chemical Entity (NCE) status and an Orange Book listing from the FDA, providing a minimum of five years of regulatory exclusivity. The company's U.S. patents and pending applications are projected to protect YCANTH from generic competition until 2034-2041, with CEO Ted White expecting full patent protection for the next decade.